ExpreS2ion Biotech Holding AB (EXPRS2) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ExpreS2ion Biotech Holding AB (EXPRS2) has a cash flow conversion efficiency ratio of -0.965x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-25.49 Million ≈ $-2.74 Million USD) by net assets (Skr26.42 Million ≈ $2.84 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see EXPRS2 stock market capitalisation for the company's overall valuation and market capitalisation.
ExpreS2ion Biotech Holding AB - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how ExpreS2ion Biotech Holding AB's cash flow conversion efficiency has evolved over time, based on yearly financial data.
ExpreS2ion Biotech Holding AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ExpreS2ion Biotech Holding AB ranked by their cash flow conversion efficiency. See EXPRS2 debt coverage from operations to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Charles & Colvard Ltd
NASDAQ:CTHR
|
-0.051x |
|
India Capital Growth Fund
LSE:IGC
|
-0.009x |
|
CO2 Gro Inc
V:GROW
|
-0.506x |
|
Infield Minerals Corp
V:INFD
|
-0.006x |
|
RED LAKE GOLD INC.
F:P11A
|
-1.043x |
|
Beyon 3D Ltd
TA:BYON
|
N/A |
|
Rapid Nutrition PLC
PA:ALRPD
|
-1.217x |
|
Savannah Energy PLC
LSE:SAVE
|
0.060x |
Annual Cash Flow Conversion Efficiency for ExpreS2ion Biotech Holding AB (2016–2025)
The table below shows the annual cash flow conversion efficiency of ExpreS2ion Biotech Holding AB from 2016 to 2025. View EXPRS2 live share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr35.69 Million ≈ $3.84 Million |
Skr-40.90 Million ≈ $-4.40 Million |
-1.146x | -117.64% |
| 2024-12-31 | Skr64.42 Million ≈ $6.93 Million |
Skr-33.93 Million ≈ $-3.65 Million |
-0.527x | +65.88% |
| 2023-12-31 | Skr65.36 Million ≈ $7.03 Million |
Skr-100.89 Million ≈ $-10.86 Million |
-1.543x | -60.10% |
| 2022-12-31 | Skr103.33 Million ≈ $11.12 Million |
Skr-99.61 Million ≈ $-10.72 Million |
-0.964x | -196.42% |
| 2021-12-31 | Skr140.35 Million ≈ $15.10 Million |
Skr-45.65 Million ≈ $-4.91 Million |
-0.325x | -69.19% |
| 2020-12-31 | Skr94.55 Million ≈ $10.17 Million |
Skr-18.18 Million ≈ $-1.96 Million |
-0.192x | -101.63% |
| 2019-12-31 | Skr-1.08 Million ≈ $-116.12K |
Skr-12.69 Million ≈ $-1.37 Million |
11.762x | +858.09% |
| 2018-12-31 | Skr8.30 Million ≈ $893.32K |
Skr-12.88 Million ≈ $-1.39 Million |
-1.551x | -21.43% |
| 2017-12-31 | Skr6.74 Million ≈ $725.01K |
Skr-8.61 Million ≈ $-926.36K |
-1.278x | -134.40% |
| 2016-12-31 | Skr12.88 Million ≈ $1.39 Million |
Skr-7.02 Million ≈ $-755.57K |
-0.545x | -- |
About ExpreS2ion Biotech Holding AB
ExpreS2ion Biotech Holding AB (publ), a clinical-stage biotechnology company, develops protein-based immunotherapies and vaccines for oncology and infectious diseases in the Nordics and internationally. The company's lead asset is ES2B-C001, an immunotherapy candidate, which is in Phase 1 clinical trials for breast cancer that targets the human epidermal growth factor receptor 2, as well as vacci… Read more